Navigation Links
ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Date:11/10/2010

perpetually amplifying the destructive inflammatory cascade.  C5aR also mediates smooth muscle contraction, increasing vascular permeability and altering blood flow.  If left untreated, ANCA-associated vasculitis may lead to renal and pulmonary failure and is often fatal.  Current therapies include toxic treatments such as cyclophosphamide and high dose corticosteroids.  Under an alliance between ChemoCentryx and GlaxoSmithKline's (GSK's) Center of Excellence for External Drug Discovery (ceedd), GSK has the right to exercise an option to license CCX168 after Phase II clinical trials.  

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... Broadest, Most Comprehensive Survey Provides New Benchmark on MRSA,in Healthcare ... today by APIC: , , WHAT:, ... Methicillin-resistant, Staphylococcus aureus (MRSA), ... in U.S. healthcare facilities., -- MRSA ...
... LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.,(OTCBB:NRGX) ... issue,of the journal The Lancet of positive results ... disease and the first report of,direct gene transfer ... adult,neurodegenerative disease., The open label Phase 1 study, ...
Cached Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:12/19/2014)... Mobile Spa, has announced they now have a Virtual ... into a utopia for the Long Island community where the ... Tour showcases the beauty of the Spa On Wheels which ... The Virtual Tour shows viewers each of the rooms in ... Marla Kaplan-Pelle, Director states " It's hard to imagine that ...
(Date:12/19/2014)... Oshkosh, Wisconsin (PRWEB) December 19, 2014 ... country music performer is again returning to the stage ... joining her husband for concert performances, and the successful ... show was originally announced. , Visit Ticketability.com ... for the newly-announced Detroit shows at fair prices. , ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- A new study suggests ... to severe hot flashes and night sweats -- and ... Hot flashes are common during menopause, affecting about 60 ... affect women after menopause, since they then face a ... findings suggest women who exhibit moderate or severe menopausal ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Prostaglandin analogue eye drops -- ... the risk of vision loss in patients with the ... led by David Garway-Heath, of the Moorfields Eye Hospital ... for more than 500 people newly diagnosed with open-angle ... and one of the leading causes of blindness. ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
Breaking Medicine News(10 mins):Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... , ... (Vocus) February 3, 2009 -- , , , , ,Who: ... their parents, , ,What: To kick off Children,s Dental Health Month, ... Children,s Dental Services) will be offered on a first-come, first-served basis. ...
... The American College of Medical Genetics Foundation (ACMGF) has ... new ACMG Foundation website is not only a great way ... see first-hand how the initiatives of the ACMG and the ... of genetic discoveries into better patient care," says R. Rodney ...
... in the CaribbeanCHICAGO, Feb. 3 Chicago,s ... is working with the government of Guyana to implement ... by HIV/AIDS in this high-need region of the world. ... individuals, will provide a more secure future for children ...
... of the country, , , TUESDAY, Feb. 3 (HealthDay News) -- ... the states, according to a new study from the U.S. ... analysis showed that mammography use increased slightly from 2000 to ... Alabama. But it fell by 0.3 to 5.3 percent in ...
... because doses used were so high , , TUESDAY, Feb. ... to treat children with attention-deficit hyperactivity disorder (ADHD), caused ... those seen with cocaine, a new study shows. , ... City, said the findings suggest that chronic exposure to ...
... second-hand smoke and alcohol significantly raises the risk of ... Alabama at Birmingham (UAB). , The finding adds to ... for health as a combination, beyond the individual exposure ... the UAB Department of Environmental Health Sciences and a ...
Cached Medicine News:Health News:Free Dental Screenings Every Tuesday in February To Celebrate Children's Dental Health Month 2Health News:American College of Medical Genetics Foundation Unveils New Website: ACMG Foundation Supports Medical Genetics Research, Education and Practice 2Health News:Chicago HIV/AIDS Organization Works with Government of Guyana to Implement New Programs to Help Children Affected by Epidemic 2Health News:Fewer Women Are Having Mammograms 2Health News:Mouse Study Suggests ADHD Drug Might Be Addictive 2Health News:Mouse Study Suggests ADHD Drug Might Be Addictive 3Health News:Tobacco smoke and alcohol harm liver worse as combo 2
... Osteon Bone Graft Substitutes a natural alternative ... cadaver bone, but such grafts may introduce ... transmission. Interpore Cross has developed the Pro ... address these needs, offering surgeons a broad ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Halle bone curette, 8 1/4, oval, malleable shaft, 4 mm wide....
Medicine Products: